Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 25 analyst ratings
Hold
Strong Buy 16%
Buy 20%
Hold 56%
Sell 8%
Strong Sell 0%

Bulls say

Amgen is poised for continued success, with a strong portfolio of flagship drugs, including red blood cell boosters and immune system boosters, as well as a growing oncology and biosimilars franchise, and recent acquisitions adding further potential for growth. Their current pipeline and key catalysts, such as their Lp(a) program and phase 3 Sjogren's data, also provide opportunities for future growth. Strong commercial performance, as seen in their recent Rx data and continued growth in key products like Repatha, supports a positive outlook for Amgen's stock. However, potential risks, such as competition in the obesity market or biosimilar erosion of key products, should also be considered.

Bears say

Amgen is facing several potential risks, such as delays or setbacks in competitors' obesity programs, competition for its bone-strengthening drugs from biosimilars, and negative tax decisions in ongoing litigation with the IRS, that could impact its future earnings and overall growth. Even though there is room for speculation about its latest drug data, Amgen has been positioned as a leader in leveraging Repatha for the niche drug market and is expected to see positive tailwinds from the trajectory of positive class data. With an estimated 75% probability of success for its drug olpasiran, peak sales of $4.4 billion are anticipated, mainly driven by its use in secondary prevention for patients with established ASCVD.

Amgen (AMGN) has been analyzed by 25 analysts, with a consensus rating of Hold. 16% of analysts recommend a Strong Buy, 20% recommend Buy, 56% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 25 analysts, Amgen (AMGN) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $394.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $394.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.